An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Brendan McDermid | Reuters
Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according to an update on the Food and Drug Administration’s drug shortage database on Wednesday.
All doses of Zepbound and Mounjaro besides the 2.5-milligram versions of both treatments are in a shortage. A previous update said some doses of both drugs would have limited availability through April.
The new update suggests that the insatiable demand for a buzzy class of weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and its main rival, Novo Nordisk, work to increase production of those treatments.
Many patients are struggling to find…
